Today: 20 May 2026
Browse Category

EPA:ABVX.PA 10 December 2025 - 12 January 2026

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax shares fell 9.49% to 99.20 euros in Paris on Thursday, reversing a 6% gain from the previous day. Volume reached about 246,000 shares amid anticipation of Phase 3 trial results for obefazimod in late Q2 2026. A U.S. Form 144 filing showed Sofinnova Crossover I SLP intends to sell up to 1,000,000 ADS. BTIG raised its price target on Abivax to $150 and maintained a “Buy” rating.
8 January 2026
·
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····

Stock Market Today

  • Verra Mobility (VRRM) Stock Under Pressure Amid Valuation Discount and Growth Uncertainty
    May 19, 2026, 6:44 PM EDT. Verra Mobility (VRRM) shares have declined about 13% in the past month and nearly 41% year-to-date, reflecting sustained weakness. The stock trades at $13.28, significantly below an estimated fair value of $24.86, suggesting it may be undervalued by 46.6%. This valuation is based on projected earnings growth, margin expansion, and adoption of smart city and cashless tolling technologies. However, risks include contract concentration near New York and margin pressures from program investments. Investors face mixed sentiment as market participants balance potential growth against execution uncertainties. Careful review of key rewards and risks is advised before reassessing positions in VRRM.

Latest articles

Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
8×8 Jumps on Profit Beat as Margins Stay Under Pressure

8×8 Jumps on Profit Beat as Margins Stay Under Pressure

20 May 2026
8x8 shares rose 14.1% to $2.75 in after-hours trading after reporting fourth-quarter revenue of $185.2 million, up 5%, and adjusted diluted earnings of 11 cents a share. Usage-based revenue grew over 70% year-over-year, making up 23% of service revenue. The company posted GAAP net income of $0.1 million, compared to a $5.4 million loss a year earlier. Fiscal 2027 revenue is forecast at $727 million to $747 million.
JetBlue axes 12 routes; Fort Lauderdale responds

JetBlue axes 12 routes; Fort Lauderdale responds

20 May 2026
JetBlue will end all flights at Manchester-Boston Regional Airport on July 8 and cut nine other East Coast routes, shifting capacity to Fort Lauderdale. The move follows Spirit Airlines’ shutdown and increased competition in South Florida. JetBlue said Fort Lauderdale revenue per seat mile rose 5% in the first quarter. Manchester officials expressed disappointment, noting JetBlue made up no more than 5% of airport traffic.
Go toTop